fda warning letters glp-1 compounding september 2025 issues 30 to online compounders September 8, 2025: FDA launches

A (very severe), B (relatively severe), C (generally severe), D (not severe but symptomatic) and E (no inflammation)

Dont miss Food Navigators broadcast series on Weight Management Join industry leaders and scientists on November 13 & 19 as we explore how the rise of GLP-1 weight-loss drugs is disrupting the food & beverage space and uncover how functional foods, bioactive ingredients and next-gen formulations can reshape satiety, metabolism and brand opportunity

2024 Jul 25;11:100121

In the digestive system, individuals might experience nausea, vomiting, diarrhea, abdominal pain, or bloating

Current standard-of-care treatments focus primarily on preventing secondary damage through surgical intervention and supportive care

& Long, D